GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (FRA:BX2) » Definitions » Short Percentage of Float

BioXcel Therapeutics (FRA:BX2) Short Percentage of Float


View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.


Competitive Comparison of BioXcel Therapeutics's Short Percentage of Float

For the Biotechnology subindustry, BioXcel Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioXcel Therapeutics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioXcel Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where BioXcel Therapeutics's Short Percentage of Float falls into.



BioXcel Therapeutics (FRA:BX2) Business Description

Traded in Other Exchanges
Address
555 Long Wharf Drive, 12th Floor, New Haven, CT, USA, 06511
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

BioXcel Therapeutics (FRA:BX2) Headlines

No Headlines